Sleight of hand in trial design: Average behaviour is not average, not all new information is really new

International Journal of Clinical Practice

Volumn 63, Issue 4, 2009, Pages 534-535

  Reynolds, T ^a  

^a QUEEN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN;

CHOLESTEROL BLOOD LEVEL; EDITORIAL; EXPERIMENTAL DESIGN; HUMAN; PATIENT SELECTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TREATMENT RESPONSE;

CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; STATISTICS AS TOPIC;

EID: 62549099489     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02024.x     Document Type: Editorial

References (5)

1. Scneider SH. What is 'dangerous' climate change? Nature 2001 411 : 17 9.
2. Farnier M, Averna M, Missault L et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS Study. Int J Clin Pract 2009 63 : 547 59.
3. O'Neill FH, Patel DD, Knight BL et al. Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2001 21 : 832 7.
4. Peter Jones, Stephanie Kafonek, Irene Laurora, Donald Hunninghake, for the CURVES Investigators. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (The CURVES Study). Am J Cardiol 1998 81 : 582 7.
5. Ziajka PE, Reis M, Kreul S, King H. Initial low-density lipoprotein response to statin therapy predicts subsequent low-density lipoprotein response to the addition of ezetimibe. Am J Cardiol 2004 93 : 779 80.